Antihyperglycemic effects of Lysiphyllum strychnifolium leaf extract in vitro and in vivo
Issued Date
2023-01-01
Resource Type
ISSN
13880209
eISSN
17445116
Scopus ID
2-s2.0-85145955988
Pubmed ID
36625086
Journal Title
Pharmaceutical Biology
Volume
61
Issue
1
Start Page
189
End Page
200
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Biology Vol.61 No.1 (2023) , 189-200
Suggested Citation
Goli A.S., Sato V.H., Sato H., Chewchinda S., Leanpolchareanchai J., Nontakham J., Yahuafai J., Thilavech T., Meesawatsom P., Maitree M. Antihyperglycemic effects of Lysiphyllum strychnifolium leaf extract in vitro and in vivo. Pharmaceutical Biology Vol.61 No.1 (2023) , 189-200. 200. doi:10.1080/13880209.2022.2160771 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82610
Title
Antihyperglycemic effects of Lysiphyllum strychnifolium leaf extract in vitro and in vivo
Author's Affiliation
Other Contributor(s)
Abstract
Context: Lysiphyllum strychnifolium (Craib) A. Schmitz (LS) (Fabaceae) has traditionally been used to treat diabetes mellitus. Objective: This study demonstrates the antidiabetic and antioxidant effects of aqueous extract of LS leaves in vivo and in vitro. Materials and methods: The effects of aqueous LS leaf extract on glucose uptake, sodium-dependent glucose cotransporter 1 (SGLT1) and glucose transporter 2 (GLUT2) mRNA expression in Caco-2 cells, α-glucosidase, and lipid peroxidation were evaluated in vitro. The antidiabetic effects were evaluated using an oral glucose tolerance test (OGTT) and a 28-day consecutive administration to streptozotocin (STZ)-nicotinamide (NA)-induced type 2 diabetic mice. Results: The extract significantly inhibited glucose uptake (IC50: 236.2 ± 36.05 µg/mL) and downregulated SGLT1 and GLUT2 mRNA expression by approximately 90% in Caco-2 cells. Furthermore, it non-competitively inhibited α-glucosidase in a concentration-dependent manner with the IC50 and Ki of 6.52 ± 0.42 and 1.32 µg/mL, respectively. The extract at 1000 mg/kg significantly reduced fasting blood glucose levels in both the OGTT and 28-day consecutive administration models as compared with untreated STZ-NA-induced diabetic mice (p < 0.05). Significant improvements of serum insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and GLUT4 levels were observed. Furthermore, the extract markedly decreased oxidative stress markers by 37–53% reduction of superoxide dismutase 1 (SOD1) in muscle and malondialdehyde (MDA) in muscle and pancreas, which correlated with the reduction of MDA production in vitro (IC50: 24.80 ± 7.24 µg/mL). Conclusion: The LS extract has potent antihyperglycemic activity to be used as alternative medicine to treat diabetes mellitus.